Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Johnson and Johnson
McKesson
McKinsey
Harvard Business School

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Fosbretabulin


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Fosbretabulin?

Fosbretabulin is an investigational drug.

There have been 18 clinical trials for Fosbretabulin. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2015.

The most common disease conditions in clinical trials are Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic, and Ovarian Neoplasms. The leading clinical trial sponsors are Mateon Therapeutics, National Cancer Institute (NCI), and Case Comprehensive Cancer Center.

There are three hundred and eighty-nine US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Fosbretabulin
TitleSponsorPhase
Fosbretabulin With Everolimus in Neuroendocrine Tumors With ProgressionLowell Anthony, MDPhase 1
FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian CancerMateon TherapeuticsPhase 2/Phase 3
Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid CancerMateon TherapeuticsPhase 3

See all Fosbretabulin clinical trials

Clinical Trial Summary for Fosbretabulin

Top disease conditions for Fosbretabulin
Top clinical trial sponsors for Fosbretabulin

See all Fosbretabulin clinical trials

US Patents for Fosbretabulin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fosbretabulin ⤷  Try it Free Pyrrolidinone derivatives as MetAP-2 inhibitors Merck Patent GmbH (Darmstadt, DE) ⤷  Try it Free
Fosbretabulin ⤷  Try it Free Pharmaceutical compositions Momenta Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Try it Free
Fosbretabulin ⤷  Try it Free Small molecule drug conjugates Eth Zurich (Zurich, CH) ⤷  Try it Free
Fosbretabulin ⤷  Try it Free Anti-vasculature and anti-tubulin combretastatin analogs for treatment of cancer XAVIER UNIVERSITY OF LOUSIANA (New Orleans, LA) ⤷  Try it Free
Fosbretabulin ⤷  Try it Free Heteroaryl compounds as IRAK inhibitors and uses thereof Merck Patent GmbH (Darmstadt, DE) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fosbretabulin

Drugname Country Document Number Estimated Expiration Related US Patent
Fosbretabulin Argentina AR101414 2034-08-04 ⤷  Try it Free
Fosbretabulin Australia AU2015299431 2034-08-04 ⤷  Try it Free
Fosbretabulin Brazil BR112017000730 2034-08-04 ⤷  Try it Free
Fosbretabulin Canada CA2957154 2034-08-04 ⤷  Try it Free
Fosbretabulin China CN106660989 2034-08-04 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Johnson and Johnson
McKesson
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.